Senate invoice proposes insulin worth cap for diabetes sufferers

In this photo illustration, Novo Nordisk insulin pens are on display on March 14, 2023 in Miami, Florida.

Joe Raedle | Getty Images

A bipartisan Senate bill introduced this week would limit the price of insulin to $35 a month for people with private insurance.

The bill, drafted by Sens. Jeanne Shaheen, DN.H., and Susan Collins, R-Maine, comes two months after President Joe Biden called on Congress during his State of the Union address to extend the insulin price cap to millions of people with diabetes who are privately insured.

“Americans living with diabetes and those who love them can no longer wait for Congress to act — the time is now,” Shaheen and Collins said in a statement Friday.

“We urge the Senate leadership to submit this bill for consideration as soon as possible,” the senators said. The law was introduced on Thursday.

Biden’s Inflation Reduction Act, which went into effect last year, capped the price of insulin for seniors on Medicare at $35 per month.

But efforts to include people with private insurance were stymied by Republican opposition last year in Congress.

More than 2 million diabetics who take insulin are privately insured, according to the Health Ministry.

About 150,000 patients who take insulin are uninsured, according to HHS.

In March, Eli Lilly, Novo Nordisk and Sanofi announced they were reducing the prices of their top insulin products in response to mounting public pressure to address rising costs.

CNBC Health & Science

Read CNBC’s latest global health coverage:

These three drug companies control 90% of the global insulin market, according to HHS.

Shaheen and Collins said Congress must step in and legislate the price cap to ensure insulin is affordable for patients.

“We are encouraged by the proactive steps taken by private companies, but this is a drop in the bucket of the measures needed to bring prices down across the board and keep them there,” the senators said.

The legislation would require that beginning in January 2024, private insurance plans limit the price patients pay to no more than $35 per month and waive deductibles for at least one of each insulin type and dosage form.

Types of insulin include fast, short, medium, long-acting, and premixed. Dosage forms include vials, pens, and inhalers.

In 2025, legislation would cap the amount patients pay at the lower of two possible rates — $35 a month, or 25% of the manufacturer’s list price.

The bill also seeks to rein in pharmacy service administrators, the intermediaries who negotiate drug prices with drug manufacturers on behalf of health plans.

Although pharmacy service administrators are said to negotiate lower prices, they have come under scrutiny for pocketing some of the rebates and rebates they receive from manufacturers.

Senate legislation would require administrators of pharmacy benefits to pass on 100% of discounts and rebates they negotiate off the insulin manufacturer’s list price to health insurers, which could help lower premiums for patients.

The bill would also give the Food and Drug Administration the power to expedite approval of biologic products like insulin that resemble branded products, which could help increase competition and drive down prices.

So far, the FDA has only approved two insulins — Rezvoglar and Semglee — that are interchangeable with branded products. These are manufactured by Lilly and Mylan Pharmaceuticals respectively.

Correction: The legislation was introduced on Thursday. A previous version of this story got the date wrong.

Afroman formally recordsdata papers to run for president in 2024

Afroman has announced that he is running for US President in 2024 and made it official this week! The rapper submitted the paperwork to the Federal Elections Commission required to run for President in the United States

While the move may come as a shock to some, he first announced he would be competing in the race in December. During a performance in Missouri, he told the crowd about his plans to take over the White House.

RELATED: Afroman’s home was raided by Ohio police while reportedly looking for drugs at the ‘Because I Got High’ rapper’s home

The rapper Before I Got High is reportedly planning to address national marijuana legalization in his campaign. However, there are no additional details about his campaign or stances on other political issues.

The documents were filed on April 18, two days before the unofficial marijuana holiday known as 4/20, which occurs on April 20 annually.

Campaign manager asks for support for ‘our cannabis commander in chief’

Afroman campaign manager Jason Savage told the outlet that they are asking for support as “Afroman takes on this great and worthy cause as our cannabis commander in chief.”

His presidential bid comes amid a legal battle with the Ohio Police Department. Last August, the Adams County Sheriff’s Department barged into his home, guns drawn, looking for narcotics. Afroman was not at his home in Ohio at the time, but in Chicago.

After the search, Afroman shared footage of the police search on social media posts and a music video for Will You Help Me Repair My Door.

In response, seven officers involved in the raid sued the rapper in March for using their likenesses and portrayals “without the authorization of either of the plaintiffs.” They claim to have “suffered humiliation, ridicule, mental distress, disgrace and loss of reputation.”

Speaking to TMZ, campaign manager Savage highlighted the ongoing lawsuit.

“Afroman’s continued pursuit by the notoriously corrupt Adams County Sheriff’s Department underscores perfectly that this corruption of leadership has trickled down to law enforcement agencies across the country. Criminal justice reform and federal legalization of marijuana remain two of the main pillars of his campaign platform.”

So far, Afroman is the first major celebrity to make her 2024 presidential aspirations official.

Procter & Gamble (PG) Outcomes Q3 2023

Procter & Gamble on Friday reported quarterly earnings and sales that beat analysts’ expectations as higher prices helped offset lower demand for its products, particularly in Europe.

The company, which owns household brands like Febreze, Charmin, and Tide, also raised its guidance for fiscal 2023 organic sales growth to 6%, from its previous range of 4% to 5%.

P&G shares up more than 4% in morning trade.

Here’s what the company reported for the quarter ended March 31, compared to Wall Street expectations based on a survey of analysts by Refinitiv:

  • Earnings per share: $1.37 versus $1.32 expected
  • Revenue: $20.07 billion versus $19.32 billion expected

P&G reported net income of $3.4 billion, or $1.37 per share, for the third quarter, up from $3.36 billion, or $1.33 per share, a year ago.

net sales rose 4% to $20.07 billion. Organic revenue, which excludes the impact of foreign currencies, acquisitions and divestitures, rose 7% in the quarter.

But the company’s volume, which excludes price and currency changes, fell 3% as consumers turned to cheaper alternatives. Across the portfolio, P&G prices rose 10% year over year. The company raised prices again in the U.S. and Europe in the fiscal third quarter, CFO Andre Schulten said during a press briefing.

This is the fourth consecutive quarter of contracting volume for the consumer giant. In a separate conference call with analysts, Schulten said he expects it will be a few more quarters before the company can return to volume growth. He downplayed volume declines during both calls on Friday, striking an upbeat tone and saying consumption trends around the world had stabilized.

Volume improved sequentially since the company’s second quarter, Schulten said. He added that quarterly volume was down just 2% year over year excluding P&G’s business in Russia, where the company has scaled back operations and advertising since the Kremlin launched the war in Ukraine last year has begun.

Schulten said Europe is a pain point as consumers there turn to private label products. He anticipates that the market will continue to weigh on volume.

However, Schulten said volume was increasing in the US, the company’s largest market. He pointed to another bright spot in China, P&G’s second-largest market, which is finally recovering from Covid lockdowns and seeing an improvement in consumer confidence. P&G is also still waiting for travel shopping in China to pick up again. Travel retail is a key revenue stream for SK-II, an upscale skin care brand owned by P&G.

All of P&G’s businesses reported declining volumes for the quarter, with the exception of its health and beauty units, both of which posted volume growth of just 1%.

P&G’s Textile and Home Care segment, which includes brands like Tide, Swiffer and Mr. Clean, saw the sharpest decline among the company’s businesses, down 5% in volume. According to P&G, the main volume declines were in Europe.

The baby, feminine and family care segment saw a 4% decline in volume. The division, which includes Pampers, Bounty and Charmin, also saw volumes decline in Europe. The company said demand for its diapers is lower there.

P&G’s grooming business, which owns Gillette and Venus razors, was down 1% in volume. The unit generally underperformed the rest of the P&G portfolio, but performed relatively better this quarter. However, reduced demand for his devices caused the unit to decline in volume.

Failures of the SVB, the signature financial institution set off the chance identification plan of the treasury

The US Treasury Secretary testifies before the Senate Appropriations Subcommittee on Financial Services March 22, 2023 in Washington, DC.

Win Mcnamee | Getty Images

WASHINGTON — The Treasury Department’s risk oversight arm on Friday proposed new tools to detect problems in the U.S. financial system, more than a month after the collapse of Silicon Valley Bank And signature bank efforts to avert further damage to the economy.

The Financial Stability Oversight Council voted to approve a financial stability framework for public feedback. The plan, which will provide Americans with greater transparency about the council’s operations and the identification of systemic problems, will be the first such measure he has released.

“This framework outlines common vulnerabilities and transmission channels through which shocks can propagate through the financial system. And it sets out how the Council is considering the tools it will use to address those risks,” Treasury Secretary Janet Yellen said in pre-release comments.

Yellen said the council “does not generally prioritize one type of instrument over another” in an attempt to prevent problems in the financial system. It plans its response to a specific risk after an assessment, she said.

“The framework emphasizes the importance of a comprehensive and rigorous approach,” said Yellen. “Tackling the multiple financial vulnerabilities that exist today—and may arise tomorrow—requires a wide range of flexible tools.”

The Treasury Department, along with the Federal Deposit Insurance Corp. depositors as they feared repercussions from the collapse of SVB and Signature Bank, some of which powered digital currency exchanges. Federal regulators last month closed both banks, confiscated their deposits, sold both companies to other financial institutions and averted the biggest banking crisis since 2008.

CNBC Policy

Read more about CNBC’s political coverage:

The FSOC also voted to release guidance proposals that would allow it to use Congressional powers to nominate non-bank financial firms for Federal Reserve Board oversight as needed.

Yellen did not identify which companies might be named, only saying that oversight of more institutions “is an important preventive tool to address systemic risk that may emanate from a non-bank financial company whose activities or distress threaten the financial system.” could”.

Rep. Maxine Waters, D-Calif., senior member of the House Financial Services Committee, welcomed the council’s move to nominate non-banks for financial oversight, which she says has been obstructed by the Trump administration.

“The unexpected failures of SVB and Signature Bank last month and the resulting banking crisis are a stark reminder that FSOC and our regulators must remain vigilant and seek to address vulnerabilities in our financial system promptly and quickly,” Waters said.

Both proposals will be released for a 60-day comment period.

AI is on the coronary heart of HIMSS to scale back paperwork

Participants of the HIMSS conference walk around the exhibition area

Source: HIMSS

Debates about artificial intelligence and its role in healthcare were the focus of this week’s HIMSS Global Health Conference in Chicago, which brought together more than 35,000 physicians, other healthcare professionals, executives and engineers to discuss the latest advances in healthcare and technology.

companies such as Microsoft, Google And Amazon they prominently promoted new health applications for AI at booths across a sprawling exhibition space, and expert panels answered questions on how the technology can be used to address industry-wide challenges such as staff shortages and physician burnout.

related investment news

CNBC Investing Club

Many healthcare organizations and companies have used AI in various capacities for years, but a subset known as generative AI exploded into public awareness late last year when Microsoft-backed OpenAI launched its viral new chatbot called ChatGPT. Generative AI refers to programs that can use fairly complicated end-user prompts to generate text or images.

Just as generative AI has captured the attention of the general public, it has also captivated the medical community.

AI was the focus of the opening speech at the HIMSS conference, and HIMSS CEO Hal Wolf opened the discussion by revealing that he asked ChatGPT how to solve global healthcare challenges. The Healthcare Information and Management Systems Society (HIMSS) hosts the conference every year.

Wolf jokingly posed the question to ChatGPT, but David Rhew, global chief medical officer at Microsoft, told CNBC in an interview that generative AI could really be “transformative” to solve big problems in the healthcare industry.

“The opportunity to apply these large language models and artificial intelligence to clinical workflows is tremendous, and we need to be responsible about it,” he said.

For Rhew, that means starting with “high-impact, low-risk” uses of the technology, such as streamlining administrative tasks.

The development of diagnostic or direct patient-centric generative AI applications is associated with higher risk as it raises significant regulatory questions for companies, academics and federal agencies such as the Food and Drug Administration. Rhew said to think of AI as if the healthcare industry has just been introduced into a car, while stop signs, traffic lights or roads have not yet been created.

“We have yet to figure out how to do this together,” he said.

HIMSS CEO Hal Wolf speaks at the HIMSS conference

Source: HIMSS

But in the meantime, administrative or “back office” tasks require less regulatory oversight and there is a real need for efficient solutions as office work is often onerous for clinicians.

A 2016 study funded by the American Medical Association found that for every hour a doctor spends with a patient, they spend an additional two hours on administrative work. The study states that physicians also tend to do an extra hour or two of office work outside of work hours.

Similarly, in 2017, the Journal of the Association of American Medical Colleges published a survey in which respondents indicated that about 24% of their working hours are spent on administrative tasks. More than two-thirds of physicians surveyed said administrative tasks “negatively affect their ability to provide quality care.”

HIMSS participants told CNBC they believe generative AI can help with these tasks.

Let AI do the office work

On Monday, Microsoft announced an expanded partnership with Epic Systems, a healthcare software company that helps hospitals and other healthcare systems store, share, and access electronic medical records. More than 160 million people use Epic’s MyChart software, which gives patients direct access to their health information and their care team.

Epic’s first application of AI technology automatically generates draft responses to the messages doctors receive from patients via MyChart. Doctors don’t have to use the proposed draft at all, but it saves them time when editing or sending it.

Seth Hain, senior vice president of R&D at Epic, told CNBC in an interview that AI could serve as a powerful hypothesis generation tool for doctors in the future. He said they will be able to ask patient-specific questions such as: What do you think I should look at next regarding this issue?

Peter Lee, corporate vice president of research and incubations at Microsoft, told CNBC that an early look at Epic’s AI developments brought tears to his eyes.

“It just blew me away,” he said.

Nuance Communications, a speech recognition subsidiary of Microsoft, also announced a clinical note-taking application called DAX Express ahead of HIMSS in March. DAX Express is designed to help reduce the administrative burden for physicians by automatically creating a clinical note within seconds of a patient visit.

In a live demo at HIMSS, Nuance previewed future projects and showcased the capabilities of DAX Express, which was met with gasping breaths and exclamations of joy from a few doctors, nurses and caregivers in the room.

More than 35,000 people attended the HIMSS conference in 2023

Source: HIMSS

Other companies are also working to use generative AI to reduce administrative burdens.

Amazon Web Services on Monday announced an expanded partnership with Philips, a healthcare technology company based in the Netherlands. AWS has already supported many of Philips’ existing cloud-based and AI initiatives, such as those that help radiologists analyze scans and medical images faster – even from home.

However, Monday’s announcement means that Philips will also leverage AWS generative AI technology to simplify its clinical workflows and enhance its imaging capabilities even further.

“What’s most exciting is the fact that we’re approaching a precipice where we have this tipping point where we’re making right easy,” said Shez Partovi, Philips chief innovation and strategy officer, in an interview with CNBC. “And right now, in most technology, the right thing is many clicks away.”

Partovi said that all the small tasks doctors have to do are like “death by 1,000 cuts,” so using AI to address administrative challenges can have a real impact on doctors’ quality of life.

On Tuesday, 3M Health Information Systems also announced that it is also working with Amazon Web Services’ machine learning and generative AI to reduce the administrative burden for physicians. 3M HIS powers a conversational AI platform used by more than 300,000 physicians, and the company said in a press release that AWS technology will make it easier for physicians to automate and complete accurate clinical notes in the electronic medical record.

Similarly, Google Cloud last week announced a Claims Acceleration Suite that leverages AI to streamline health insurance claim processing and pre-approval.

According to the Centers for Medicare & Medicaid Services, the current pre-approval process takes an average of 10 days. Google’s AI will help alleviate some of this administrative burden for providers by converting the unstructured data that appears in images, PDFs or other health records into a more digestible, structured format.

“They actually require a human being to go in there and take that data and put it into the system for review,” Amy Waldron, director of strategy and solutions for global health plans at Google Cloud, said during a media briefing with reporters from HIMSS. “Which makes absolutely no sense to me as someone has to take the time to put all this rich data in there and we have AI that can unlock that value.”

Generative AI has “tremendous” potential to improve managerial efficiency in healthcare, Microsoft’s Rhew said. However, as healthcare and technology companies make increasingly sophisticated advances, industry leaders, regulators, and community academics must ensure that generative AI is fair and harmless to communities.

The technology is prone to bias and discrimination when trained on health data that does not properly represent a patient population, which could ultimately lead to inadequate decision-making or treatment plans.

As a result, Rhew says, there is a collective responsibility to figure out how to use AI with care.

“It’s a transformative technology,” he said, “but we have to figure out how to use it responsibly.”

The Massive Bang Concept alum Kevin Sussman marries Addie Corridor

These weddings are out of this world.

The Big Bang Theory actor Kevin Sussman recently announced on social media that he has married a partner Addie Hall in an outdoor ceremony last weekend.

In a wedding photo posted to Instagram on April 20, Kevin wears a navy blue suit with a row of flowers on the lapels. Meanwhile, Addie donned a white dress with buttons at the bodice and lace at the skirt. She complemented her look with pearl earrings.

Kevin—who played Stuart Bloom on the CBS sitcom—captioned the pic, “Did I mention I got married this weekend?”

His Big Bang Theory family left him many celebratory messages in the comments, including Kunal Nayyarwho wrote: “Oh my gaaaawwwwwd! I love you brother.”

Lauren Lapkus wrote: “Wow! Congratulations!!” while Kate Micucci added next to heart emoji: “Congratulations!!!”

Kevin first took to Instagram with Addie in October 2020, where he posted a selfie of them together at a pumpkin patch and wrote, “After the hunt.” The pair made their red carpet debut in February 2022 at the premiere of Hulu’s The Dropout, in which Kevin portrays fictional Theranos lab director Mark Roessler.

Jim Jordan simply received caught with proof of his Hunter Biden lies

Jim Jordan and House Republicans were caught editing witness interviews to slander the SEC. of State and are pushing their Hunter Biden laptop scandal.

Here’s what Rep. Jordan’s Justice Department Republicans tweeted.

#BREAKING: Witness testimonies reveal that Secretary Blinken and the Biden campaign were behind infamous public statement by former Intel officials on Hunter Biden laptop @Jim_Jordan and @RepMikeTurner reveal HUGE news here: pic.twitter.com/bX3fpqJKPo

— House Judiciary GOP (@JudiciaryGOP) April 21, 2023

For more stories like this, subscribe to our newsletter:

Democrats on the House Judiciary Committee provided PoliticusUSA with the raw testimony in which Mike Morell testifies that he has never been asked before, Sec. Blink to write a letter through Hunter Biden’s laptop:

In a statement to PoliticusUSA, a spokesman for the House Judiciary Democrats said:

In order to smear Minister Blinken and make a three-year-old tabloid story sensationalist, Jim Jordan has published selected excerpts of a transcribed interview. To be clear, no part of this interview shows Tony Blinken or any other Biden campaign representative asking Mike Morell to write a letter through Hunter Biden’s laptop.

Mr. Morell is a former CIA Deputy Director and a decorated veteran of the intelligence community. For years he has advised leaders of both parties – including Secretary of State Mike Pompeo, who presented Mr. Morell with a Director’s Award for Distinguished Service.

At no time during his interview did Mr. Morell testify that Secretary Blinken instructed or asked him to write letters. Instead, Mr. Morell testified that Mr. Blinken sought his advice, as did many others. In response to questions posed by Chairman Jordan’s own lawyers, he testified that Mr. Blinken “in no way instructed, suggested or implied” that he write a letter through Hunter Biden’s laptop. Mr. Blinken – at that time a private individual – did not try to get hold of the letter indirectly. Mr. Morell testified that Mr. Blinken did not imply that the Biden campaign “could use some help with this” or suggested that Mr. Morell “cook something up” for the campaign to use.

Instead of focusing on issues that actually affect American families, Chairman Jordan is pulling off another political ploy. This time, he’s using taxpayers’ money to trace the origins of a letter written by private individuals expressing their private opinions, which references a story invented by Rudy Giuliani in the final days of the Trump administration.

Jim Jordan is trying to get over the fact that he cannot connect Hunter Biden’s laptop to President Biden and that files on the laptop have been modified.

The letter from 50 former national intelligence officials warning that the laptop bears the hallmarks of a Russian disinformation campaign is what Jordan and House Republicans are trying to discredit.

Jim Jordan’s investigation into Hunter Biden is failing badly, so he and his fellow Republicans are trying to fabricate evidence to justify their investigation into President Biden, but the Democrats caught them in the act and delivered the truth to the nation when Hunter Biden of the GOP Investigations go nowhere.

Jason Jim Jordan and the Republican House Judiciary were caught editing witness interviews to slander the SEC.  of State and are pushing their Hunter Biden laptop scandal.

Jason is the managing editor. He is also a White House press pool and congressional correspondent for PoliticusUSA. Jason has a bachelor’s degree in political science. His thesis focused on public policy with a specialization in social reform movements.

Awards and professional memberships

Member of the Society of Professional Journalists and the American Political Science Association

The NFL bans 5 gamers for violating playing coverage

Nick Laham | Getty Images

Five NFL players have been banned for violating the National Football League’s gambling policy, the league announced today.

The policy prohibits anyone in the NFL from engaging in any form of gambling at any league facility or venue, including practice facilities. The league said its review found no evidence inside information was used.

No games were affected by the gambling, the NFL added.

Three players — the Detroit Lions’ Quintez Cephus and CJ Moore and the Washington Commanders’ Shaka Toney — will be suspended indefinitely, at least until the end of the 2023 season, for betting on NFL games in the previous season.

These players can apply for reinstatement at the end of the season.

Two other Lions athletes — Stanley Berryhill and Jameson Williams — are suspended from playing the first six regular-season games. You can participate in offseason and preseason activities.

Quintez Cephus #87 of the Detroit Lions catches the ball for a first down in the second quarter against the Minnesota Vikings at US Bank Stadium on October 10, 2021 in Minneapolis, Minnesota. (Photo by Elsa/Getty Images)

Elsa | Getty Images Sports | Getty Images

The NFL crackdown comes as 33 states, including Michigan and Washington, DC, have introduced legal betting markets since a landmark US Supreme Court case in 2018 paved the way for states to offer legal sports betting.

Earlier this week, the major pro leagues — the NFL, NBA, NHL, MLB, WNBA, NASCAR and MLS — announced they were joining media outlets NBCUniversal and Fox in a coalition aimed at boosting the promotion of Regulate sports betting as it floods television, internet and print media.

Shortly after the suspensions were announced, the Detroit Lions said they would release Cephus and Moore. According to ESPN, the Lions became aware of the NFL’s investigation “about a month ago.”

“We are disappointed in the decisions made by Stanley and Jameson and will be working with both players to ensure they understand the seriousness of these violations and have clarity on future league rules,” said Brad Holmes, Detroit Lions executive vice president and general manager in an opinion.

Commanders said the team was aware of Toney’s suspension. “We have fully cooperated with the NFL’s investigation since receiving the notification and support the league’s findings and actions,” the team said in a statement.

Shaka Toney #58 of the Washington Commanders stands during the national anthem against the Houston Texans at NRG Stadium on November 20, 2022 in Houston, Texas.

Cooper Neil | Getty Images Sports | Getty Images

Toney’s suspension is the latest hit for the Commanders. Last week, the district attorney general said the commanders would pay $625,000 to settle allegations that the organization failed to refund fans’ ticket deposits.

Former DC Attorney General Karl Racine, who sued the Commanders last year, claimed that since 1996 the football team had promised to return fans’ deposits for premium seating, but instead pocketed the money and spent it.

A spokesman for Commanders said in a statement the team has not collected bail for more than a decade and has been “actively working to return all remaining bail since 2014.”

Disclosure: NBCUniversal is the parent company of CNBC.

Drug firm CEOs to testify earlier than Senate Well being on insulin worth

Pictured here is a Novo Nordisk insulin pen on display on March 14, 2023 in Miami, Florida.

Joe Raedle | News from Getty Images | Getty Images

The top executives of the three drug companies that control 90% of the global insulin market will testify before the Senate Health Committee on May 10 about cutting the prices of their diabetes drugs, the panel’s chairman, Sen. Bernie Sanders, said on Friday.

Those companies — Eli Lilly, Novo Nordisk, and Sanofi — announced in March that they would slash the prices of their most commonly used insulin products by 70% or more.

related investment news

CNBC Investing Club

Sanders on Friday called the move an important step forward that was the result of “public outrage and strong grassroots efforts.”

However, the independent Vermonter added that Congress must ensure that insulin, which has increased in price by more than 1,000% since 1996, is affordable for all.

“However, we must ensure that these price cuts take effect in a manner that ensures every American has the insulin they need at an affordable price,” Sanders said in a statement announcing planned testimony from Eli Lilly CEO David Ricks. Paul Hudson, CEO of Sanofi and Lars Fruergaard Jorgensen, CEO of Novo Nordisk.

The companies’ versions of insulin cost at least $275 before the announced price cuts, Sanders noted.

Eli Lilly declined to comment when asked about the scheduled hearing. A Sanofi spokesman said the company supports efforts to cut costs and believes other parts of the healthcare system need to do more to help patients. Novo Nordisk said its CEO looks forward to “a productive and collaborative discussion on this important issue.”

Top executives of the big three pharma benefit managers CVS HealthExpress scripts and Optim Rx also testify, according to Sanders’ office. These executives are David Joyner, President of CVS Health Pharmacy Services; Adam Kautzner, President of Express Scripts; and Heather Cianfrocco, CEO of Optum Rx.

Pharmacy benefit managers are the middlemen who negotiate drug prices with manufacturers on behalf of health insurance companies. PBMs have come under criticism for allegedly inflating drug prices and not passing on all the discounts they negotiate to consumers.

CNBC Health & Science

Read CNBC’s latest global health coverage:

The Health and Human Services Department estimates that 17% of patients using insulin in 2021 had to ration the drug due to high costs.

According to HHS, about 19% of privately insured insulin users have rationed the drug, and 29% of uninsured insulin users have done so.

The decision by drugmakers to cut insulin prices came a month after President Joe Biden asked Congress to cap insulin prices to $35 a month in his State of the Union address.

Biden’s Inflation Mitigation Act introduced this cap for people on Medicare, the state health insurance program for mostly seniors, but the law didn’t include those with private insurance.

According to HHS, more than 2 million patients with diabetes who take insulin have private insurance.

And about 150,000 patients who take insulin are uninsured, the department says.

On Thursday, two senators, Jeanne Shaheen, DN.H., and Susan Collins, R-Maine, introduced bipartisan legislation that would require private health insurers to raise the price of one of each insulin type and dosage form to $35 a month to limit. The draft law provides for further price reduction measures.

Types of insulin include fast, short, medium, long-acting, and premixed. Dosage forms include vials, pens, and inhalers.

Disney Ron DeSantis’ battle with lobbyists is getting into a brand new part

Disney is preparing to take its fight with Florida Gov. Ron DeSantis and his GOP allies in the state Legislature to the next level, according to people familiar with the matter.

With just weeks until the end of the Florida legislature, Disney is urging lobbyists to step up efforts to sway the Republican-controlled state legislature, including targeting land-use-related bills that could harm the company, it said the people who declined to be named so as to be able to speak freely about the issues.

A Disney spokesman declined to comment on the lobbying.

The battle between the entertainment giant and DeSantis began last year after Disney opposed what critics dubbed “don’t say gay” Florida law, which bans teaching about sexual orientation and gender identity in public schools from kindergarten through third grade .

Then, before DeSantis could strip the county where Disney is based of its self-governing status and replace the board that oversaw the area, A Disney-aligned body signed a long-term development agreement that drastically limits the governor’s control. DeSantis said state legislatures are drafting legislation to overturn this agreement.

Republican officials and business leaders have increasingly criticized DeSantis’ volleys against the company. Former President Donald Trump and former New Jersey Gov. Chris Christie — two of Florida’s governor’s potential rivals in 2024 — and even former Goldman Sachs CEO Lloyd Blankfein have pushed back on DeSantis over his struggle with the company.

Since DeSantis suggested on Monday that he wanted to develop land near Disney World, possibly by building a prison, Disney announced that “affordable and accessible housing” will open around the park in 2026.

Florida Republican Senator Blaise Ingoglia warned Disney not to fight back as he stood next to DeSantis at a news conference Monday.

“I have a few words for Disney. You will not win this fight. This governor will do it,” said Ingoglia. “One piece of advice for Disney going forward: let it go. Just let it go.”

At the same event, DeSantis vowed to reverse an agreement that would allow the Orlando amusement park to bypass a special county board staffed by DeSantis officials.

Florida Gov. Ron DeSantis answers questions during a news conference at Seminole State College in Sanford, Fla., Monday, May 16, 2022.

Joe Burbank | Orlando Sentinel | Getty Images

Shortly after DeSantis’ remarks to On Monday, Disney executives urged lobbyists to keep an eye on and aggressively crack down on any proposed legislation in Florida that could harm the company, according to a person with direct knowledge of the matter. According to DeSantis, there is a particular interest in fighting land use laws, said that person.

This person, who was not authorized to speak publicly about Disney’s plans, told CNBC that one of the land-related bills that Disney lobbyists are closely monitoring is CS/SB 1604: Land Use and Development Regulations. Ingoglia introduced the bill to the Senate and an identical measure was proposed in the House of Representatives.

Both chambers have introduced changes that could affect Disney. The measures would allow a “newly elected or appointed independent specialty governing body,” such as the DeSantis-appointed Disney District governing body, to review all development agreements and have the opportunity to vote on whether that district will re-accept the original development contract.

Both amendments were filed on Tuesday, the day after DeSantis’ press conference where he hammered Disney, according to the state Legislature website.

Disney and CEO Bob Iger don’t appear to be taking the latest moves by DeSantis and his allies lightly.

Friends of Iger say the Disney CEO may be hoping that renewed lobbying against DeSantis and allies, along with critical public perception of the governor’s actions, could dissuade enough Republican officials from siding with the governor. DeSantis effectively controls the state legislature with a GOP supermajority.

“It’s almost like every time DeSantis says these crazy things, DeSantis gets ahead of Bob,” a longtime Iger ally told CNBC. “He feels like Disney is ready for battle, but I think he’s kinda watching the governor try to float his own boat on this one.”

A Disney spokesperson told CNBC that this perception of Iger was “inaccurate.”

Bob Iger, CEO, Disney, during a CNBC interview, February 9, 2023.

Randy Shropshire | CNBC

DeSantis’ potential competitors in a presidential primary have pounced on the controversy to keep it from the Florida governor. Trump, who is running for president, and Christie, another potential 2024 candidate, have both torn DeSantis for his war with Disney.

“Disney’s next step will be to announce that they are no longer investing in Florida because of the governor — they might even announce a slow retreat or sale of certain properties or the whole thing,” Trump said in a Truth Social. post a response to DeSantis’ recent fight with the company, without citing any evidence that the company could take those steps.

Early GOP primary polls show DeSantis as the second-best candidate behind Trump. The ex-president had a massive lead in most recent polls.

CNBC Policy

Read more about CNBC’s political coverage:

The Disney feud could also cost DeSantis donors. Some Republican mega-donors who were once firmly in DeSantis’ corner for the 2024 GOP have recently called the governor’s allies to say they may not help him run for president, according to a longtime DeSantis ally . Instead, they said they could support another possible nominee in Sen. Tim Scott, RS.C., that person said.

However, there may be a way out of the protracted struggle. Prior to DeSantis’ final attack, Iger had indicated to Time that he was ready to make amends with the governor.

“I don’t see this as a situation where we get on the mattresses. Of course, if the governor of Florida wants to meet with me to discuss all of this, I’d be happy to do so,” he said.

Iger also publicly ripped DeSantis’ treatment of Disney.

Desantis vs. Disney: The war heats up in Florida